ICU Medical (NSDQ:ICUI) posted first-quarter results yesterday that beat the overall consensus on Wall Street.
The San Clemente, Calif.–based infusion therapy tech company reported profits of $23.7 million, or $1.09 per share, on sales of $318 million for the three months ended March 31, for a bottom-line gain of 41% on sales losses of -3.21% compared with Q1 2020.
Adjusted to exclude one-time items, earnings per share were $1.62, 12¢ ahead of The Street, where analysts were looking for sales of $300.9 million.
ICU Medical did not provide a financial outlook for the remainder of the fiscal year.
Shares in ICUI were down –3.95% to $205.57 apiece by midday traiding today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.